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Abstract
Background: Metabolic syndrome (MetS) is frequently characterized by elevated liver enzymes, including gamma-
glutamyl transferase (GGT) and alanine aminotransferase (ALT). Our objective was to evaluate the range of prevalence 
of MetS in apparently healthy individuals whose liver enzyme concentrations were all within-normal-range.
Methods: We have performed a cross sectional analysis on participants of the Tel-Aviv medical center inflammation 
survey (TAMCIS) recruited between the years 2003-2009. Analyzed were a cohort of 6,561 men and 3,389 women.
Results: The prevalence of MetS increased significantly from the first quintile to the fifth for both GGT and ALT, all the 
five quintiles being in the normal range. Logistic regression analysis for the presence of MetS showed crude odds ratios 
of 2.7 and 2.4 between the first and fourth quintiles and 3.6 and 3.2 for the fifth quintile in men and women 
respectively for ALT. For GGT the respective odds being 3.6 and 3.2 for the fourth quintile and 3.9 and 3.4 for the fifth 
quintile in men and women, respectively.
Conclusions: A relatively high prevalence of MetS was noted in a cohort of apparently healthy individuals with liver 
enzyme concentrations within-normal-limits. Practical consequences include the need to follow up these enzyme 
concentrations as continuous variables and to take into consideration that even relatively small elevations within the 
normal range might reflect the presence of dysmetabolism.
Background
The metabolic syndrome (MetS) is a constellation of car-
diovascular risk factors known to be associated with
increased future atherothrombotic events [1-4]. Previous
studies have shown that elevated liver enzymes concen-
trations were associated with the diagnosis of MetS and
of its components [5-9].
Little is known however, about the association between
the prevalence of the metabolic syndrome among indi-
viduals presenting with within-normal-range liver
enzymes. To the best of our knowledge, there is only one
p a pe r  w h i c h  d e m o n s t r a t ed  t h a t  ev e n  ' n o rm a l '  l ev e ls  o f
ALT are associated with the long-term development of
multiple metabolic disorders, including the MetS and
diabetes mellitus [10].
Since both elevated GGT [11-18] and ALT [19-22] have
demonstrated significant associations with both athero-
thrombotic burden and vascular risk, we have performed
a cross sectional analysis to evaluate the prevalence of the
MetS in a relatively large sample of apparently healthy
individuals in whom both GGT and ALT as well as aspar-
tate aminotransferase (AST) were all within the normal
limits.
Methods
Study population
We have presently analyzed data that has been collected
during the last five years in the Tel-Aviv medical center
inflammation survey (TAMCIS), a registered data bank
of the Israeli ministry of justice [23-29]. This is a relatively
large cohort of individuals who attended our medical
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center for a routine annual check-up and who gave their
written informed consent for participation according to
the instructions of the institutional ethics committee. A
total of 16,413 subjects gave their informed consent
(10,389 males, 6,024 females). Later, 2,071 subjects were
excluded from the analysis due to any malignancy or
immunosuppressive therapy, pregnancy, steroidal or anti-
biotic treatment or recent acute infection. We further
excluded 927 individuals due to diabetes mellitus and 221
individuals for reporting regular alcohol use of more than
1 glass per day. Finally, an additional 1,241 subjects were
excluded for missing data on any of their liver function
enzyme measurements and 2,003 individuals with any of
the three liver function enzymes concentrations that we
routinely check (ALT, GGT and AST) in whom these lev-
els were found to be above the upper limit of normal
according to our local laboratory. Following these exclu-
sions the study group comprised 9,950 individuals (6,561
men and 3,389 women).
Definitions of atherothrombotic risk factors
Results of the routine health check-up were assessed
employing certain definitions in order to recognize
atherothrombotic risk factors in individuals. These
included diabetes mellitus which was defined as a fasting
blood glucose concentration of ≥7.0 mmol/L or the intake
of insulin or oral hypoglycemic medications. Hyperten-
sion was defined as a blood pressure of ≥ 140/90 mm Hg
on two separate measurements or the use of antihyper-
tensive medications. Dyslipidemia was defined as the low
density lipoprotein cholesterol (LDL-C) or non-high den-
sity lipoprotein cholesterol (non-HDL-C) concentrations,
for individuals displaying elevated triglyceride concentra-
tions of > 2.26 mmol/L, above the recommended levels
according to the risk profile defined by the updated adult
treatment panel III (ATP III) recommendations [30] or
the use of lipid lowering medications. The diagnosis of
the metabolic syndrome was based on the joint interim
statement of the International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of
Obesity [31]. In short, elevated waist circumference was
defined as ≥94 cm (37 inches) in men and ≥80 (31.5
inches) in women as recommended for europid and mid-
dle east; elevated triglycerides (TG) were defined as ≥150
mg/dl (1.7 mmol/l) or on drug treatment for elevated
triglycerides; reduced HDL-C was defined as < 40 mg/dL
(1.0 mmol/l) in men and < 50 mg/dl (1.3 mmol/l) in
women or on drug treatment for reduced HDL-C; ele-
vated blood pressure was defined as ≥130 mm Hg systolic
blood pressure or ≥85 mm Hg diastolic blood pressure or
on antihypertensive drug treatment in a patient with a
history of hypertension; elevated fasting glucose was
defined as ≥100 mg/dl (5.55 mmol/l). Smokers were
defined as individuals who smoked at least 5 cigarettes
per day while past smokers had quit smoking for at least
30 days prior to examination.
Laboratory methods
All blood samples were drawn following a 12 hour fasting
period. Glucose was measured by the glucose oxidase sys-
tem [32]. We utilized an improved color reagent for the
determination of blood glucose by the oxidase system
using the Bayer Advia 1650 chemistry analyzer. Triglycer-
ides were measured by an adaptation of the Fossati 3 step
enzymatic reaction with the Bayer Advia 1650 chemistry
analyzer. Serum triglycerides were determined calorimet-
ri ca ll y wi t h a n e nzym e  t ha t pr oduc es  h ydr og en  pe r o x -
ide[33]. HDL-C was determined by the method
developed by Izawa et al [34] using the Bayer Advia 1650
chemistry analyzer. LDL-C was derived from the mea-
sured concentrations of total cholesterol, HDL-C and
triglycerides using the Friedwald equation: LDL-C =
Total Cholesterol - HDL-C - TG/5. GGT was determined
by the method of Szasz [35] using the Bayer Advia 1650
chemistry analyzer. ALT was determined by the modified
method in accordance with the International Federation
of Clinical Chemistry (IFCC) [36] using the Bayer Advia
1650 chemistry analyzer.
Statistical analysis
All data was summarized and displayed as mean (stan-
dard deviation [SD]) for the continuous variables and as
number of patients (expressed as a percentage) in each
group for the categorical variables. Since the triglyceride
concentrations displayed irregular distributions, we used
logarithmic transformation which converted the distribu-
tions to normal ones for all statistical procedures. There-
fore all results of triglyceride concentrations are
expressed as back-transformed geometrical means. The
One-Way Kolmogorov-Smirnov test was used to assess
the distributions. In order to characterize the population
we divided the patients in each gender into quintiles of
each of the two liver function enzymes of relevance,
including GGT and ALT, and analyzed all results accord-
ingly. For all categorical variables the Chi-square statisti-
cal test was used for assessing the statistical significance
between the quintiles, while the One-Way Analysis of
Variance was used for all continuous variables. In order
to better appreciate the magnitude of the differences in
the prevalence of the MetS between the quintiles of the
liver enzymes and in order to adjust for differences in age,
physical activity, smoking status and use of medications
that are not a part of the parameters which define the
MetS, we used logistic regression and calculated the odds
ratio for having the MetS between the quintiles of eachSteinvil et al. Cardiovascular Diabetology 2010, 9:30
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liver enzyme relative to the lower quintile. All above anal-
yses were considered significant at p < 0.05 (two tailed).
The SPSS statistical package was used to perform all sta-
tistical evaluations (SSPS Inc., Chicago, IL, USA).
Results
We have presently analyzed the results of a total of 6,561
men and 3,389 women at the mean (SD) age of 44 (11)
years. Nine hundred and sixteen men (14%) and 645
women (19%) were characterized as having the metabolic
syndrome. Epidemiological data as well as relevant bio-
chemistry for men and women are given in Tables 1 and 2
for ALT and GGT, respectively. In Tables 3 and 4 we
report the results of the logistic regression analyses for
the presence of the MetS in relation to the quintiles of
ALT and GGT, respectively. It can be seen that for ALT,
the crude odds ratios increase up to 2.7 and 2.4 in the
fourth quintile and even 3.6 and 3.2 for the fifth quintile
for both men and women. The respective odds ratios for
GGT being 3.6 and 3.2 in the fourth quintile and 3.9 and
3.4 for the fifth. The percentages of individuals with the
MetS according to quintiles of each of the within-normal-
limits liver enzyme concentrations are reported in Figure
1 for both men and women. Tables 3 &4 also evaluate the
adjusted odds ratios after adjustment for several relevant
parameters that are not a direct part of the definition of
the MetS. Those parameters include age, exercise inten-
sity, use of aspirin and statins, smoking status and alcohol
consumption. We further adjusted our models to obesity
and the results did not change significantly following all
those adjustments. Finally, in order to decrease the influ-
ence of possible confounders, we have repeated this anal-
ysis by further excluding subjects receiving statins,
fibrates, amiodarone as well as women taking oral contra-
ceptives or hormonal replacement therapy and the results
were not changed significantly (data not shown).
Discussion
We have presently shown that the MetS is prevalent in
individuals who present normal concentrations of liver
enzymes. Special attention has been given to two of them
(GGT and ALT) for whom epidemiological evidence sug-
gests an association with increased vascular risk.
Goessling et al [10] have recently studied the relationship
between aminotransferase levels and the incidence of
MetS, DM, cardiovascular disease and all cause mortality
in long-term follow-up of 2812 participants in the com-
munity-based Framingham Heart Study sample. They
demonstrated a clear association between elevated ALT
levels and the development of MetS and DM over 20
years of follow-up. They also found that ALT levels
within the normal range are associated with adverse met-
abolic outcomes [10].
In our study, we found that the prevalence of the MetS
doubles if a comparison is made between the first, second
and third quintiles of both GGT and ALT. In these quin-
tiles the concentrations of the enzymes are not only
regarded as being absolutely normal, but are actually even
in the lower range of the "normal" values. Assuming a link
between these enzymes and a potential dysmetabolic
state, the finding might suggest a relatively high sensitiv-
ity of these biomarkers to reveal the presence of dysme-
tabolism.
Elevated liver enzymes are well documented in individ-
uals with the MetS and are markers of fatty liver changes
[37]. To a certain degree these changes can be visualized
by the use of ultrasonography but this procedure is not
cost effective and lacks sufficient sensitivity and specific-
ity on a population level in screening apparently healthy
individuals with within-normal-limits concentrations of
liver enzymes. It would certainly not normally be per-
formed in asymptomatic individuals whose liver enzymes
are in the lower part of the so-called normal range and, if
Figure 1 Percentages of individuals with the metabolic syndrome (men and women) according to quintiles of each of the within-normal-
limits liver enzyme concentrations (ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase).
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Table 1: Patient characteristics* according to quintiles of ALT
Men (N = 6561) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA/χ2 P for linear 
trend
ALT<16 16≤ALT<20 20≤ALT<23 23≤ALT<29 29≤ALT≤40
N 1196 1545 1121 1460 1239 P Value
Age (years) 44 (11) 44 (11) 44 (11) 44 (11) 44 (11) 0.757 0.280
Waist (cm) 94 (10) 95 (11) 95 (11) 95 (10) 95 (10) 0.299 0.032
BMI (kg/m2) 27 (4) 27 (4) 27 (4) 27 (4) 27 (4) 0.084 0.017
Diastolic BP (mmHg) 78 (9) 78 (8) 78 (8) 78 (9) 79 (8) 0.206 0.025
Systolic BP (mmHg) 125 (15) 124 (14) 124 (15) 124 (15) 125 (14) 0.603 0.865
Alcohol consumption (glasses/week) 1.0 (1.5) 1.1 (1.6) 1.1 (1.5) 1.1 (1.6) 0.9 (1.5) 0.132 0.189
Exercise intensity (hours/week) 2.4 (3.0) 2.3 (2.7) 2.2 (2.5) 2.3 (2.9) 2.2 (2.5) 0.274 0.102
Smoking status, n (%) 0.685
Current 184 (15.7) 256 (17.0) 177 (16.0) 215 (15.0) 207 (17.1)
Former 292 (24.9) 396 (26.2) 286 (25.9) 388 (27.1) 328 (27.1)
Hypertension, n (%) 286 (23.9) 362 (23.4) 298 (26.6) 340 (23.3) 328 (26.5) 0.111
Anti-hypertensive medications, n(%) 100 (8.4) 145 (9.4) 118 (10.5) 133 (9.1) 135 (10.9) 0.192
Metabolic Syndrome, n (%) 87 (7.3) 167 (10.8) 131 (11.7) 258 (17.7) 273 (22.0) < 0.001
Glucose (mmol/L) 4.86 (0.45) 4.99 (0.50) 5.07 (0.52) 5.13 (0.53) 5.19 (0.55) < 0.001 < 0.001
HDL Cholesterol (mmol/L) 1.57 (0.39) 1.50 (0.37) 1.46 (0.36) 1.39 (0.33) 1.34 (0.31) < 0.001 < 0.001
LDL Cholesterol (mmol/L) 2.90 (0.81) 3.07 (0.82) 3.11 (0.80) 3.20 (0.82) 3.21 (0.80) < 0.001 < 0.001
Triglycerides† (mmol/L) 0.95 1.00 1.09 1.21 1.35 < 0.001 < 0.001
Statins, n(%) 117 (9.8) 142 (9.2) 97 (8.7) 129 (8.8) 124 (10.0) 0.732
Fibrates, n(%) 14 (1.2) 19 (1.2) 11 (1.0) 12 (0.8) 10 (0.8) 0.718
Women (N = 3389) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA P for linear 
trend
ALT<16 16≤ALT<19 19≤ALT<22 22≤ALT<27 27≤ALT≤35 P Value
N = 767 652 607 738 625
Age (years) 44 (11) 45 (11) 45 (11) 45 (11) 45 (11) 0.703 0.369
Waist (cm) 82 (12) 82 (12) 82 (12) 82 (12) 83 (11) 0.389 0.171
BMI (kg/m2) 25 (5) 25 (5) 25 (5) 25 (5) 26 (5) 0.489 0.248S
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Diastolic BP (mmHg) 73 (8) 74 (8) 74 (8) 74 (9) 74 (8) 0.209 0.019
Systolic BP (mmHg) 117 (15) 117 (16) 117 (15) 117 (16) 118 (16) 0.688 0.420
Alcohol consumption (glasses/week) 0.5 (1.1) 0.5 (1.1) 0.5 (1.1) 0.5 (1.2) 0.5 (1.1) 0.999 0.867
Exercise intensity (hours/week) 1.9 (2.8) 1.8 (2.5) 2.0 (3.4) 1.7 (2.3) 1.8 (2.4) 0.474 0.329
Smoking status, n (%) 0.447
Current 150 (19.9) 129 (20.3) 99 (16.6) 136 (18.8) 114 (18.7)
Former 145 (19.2) 124 (19.5) 131 (22.0) 125 (17.3) 126 (20.7)
Hypertension, n (%) 106 (13.8) 111 (17.0) 89 (14.7) 118 (16.0) 101 (16.2) 0.481
Anti-hypertensive medications, n(%) 55 (7.2) 56 (8.6) 46 (7.6) 52 (7.0) 40 (6.4) 0.648
Metabolic Syndrome, n (%) 84 (11.0) 102 (15.6) 106 (17.5) 173 (23.4) 180 (28.8) < 0.001
Glucose (mmol/L) 4.87 (0.48) 4.95 (0.50) 5.05 (0.53) 5.12 (0.55) 5.18 (0.55) < 0.001 < 0.001
HDL Cholesterol (mmol/L) 1.60 (0.37) 1.52 (0.40) 1.48 (0.37) 1.41 (0.35) 1.35 (0.33) < 0.001 < 0.001
LDL Cholesterol (mmol/L) 2.90 (0.80) 3.02 (0.80) 3.13 (0.79) 3.19 (0.81) 3.15 (0.85) < 0.001 < 0.001
Triglycerides† (mmol/L) 0.93 1.01 1.06 1.21 1.29 < 0.001 < 0.001
Statins, n(%) 59 (7.7) 40 (6.1) 48 (7.9) 41 (5.6) 33 (5.3) 0.164
Fibrates, n(%) 6 (0.8) 5 (0.8) 5 (0.8) 0 (0) 1 (0.2) 0.073
* - Data are arithmetic means (S.D.) or N (%).
† - Geometric means.
List of Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein.
Table 1: Patient characteristics* according to quintiles of ALT (Continued)S
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Table 2: Patients characteristics* according to quintiles of GGT
Men (N = 6561) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA P for linear 
trend
GGT<9 9≤GGT<12 12≤GGT<16 16≤GGT<21 21≤GGT≤42 P Value
N = 1318 1206 1443 1202 1392
Age (years) 44 (11) 44 (11) 44 (11) 44 (11) 44 (11) 0.482 0.848
Waist (cm) 95 (10) 95 (11) 95 (11) 95 (10) 95 (11) 0.721 0.165
BMI (kg/m2) 27 (4) 27 (4) 27 (4) 27 (4) 27 (4) 0.875 0.433
Diastolic BP (mmHg) 78 (8) 78 (8) 78 (9) 78 (9) 78 (9) 0.398 0.063
Systolic BP (mmHg) 124 (14) 125 (15) 123 (14) 125 (15) 124 (14) 0.062 0.244
Alcohol consumption (glasses/week) 1.1 (1.6) 1.0 (1.5) 1.0 (1.5) 1.1 (1.6) 1.0 (1.6) 0.458 0.466
Exercise intensity (hours/week) 2.4 (2.9) 2.2 (2.6) 2.3 (2.8) 2.2 (2.7) 2.3 (2.5) 0.327 0.254
Smoking status, n (%) 0.785
Current 205 (15.9) 194 (16.3) 217 (15.4) 198 (16.8) 225 (16.5)
Former 333 (25.9) 313 (26.4) 368 (26.1) 332 (28.1) 344 (25.2)
Hypertension, n (%) 301 (22.8) 298 (24.7) 347 (24.0) 329 (27.4) 339 (24.4) 0.113
Anti-hypertensive medications, n(%) 120 (9.1) 117 (9.7) 131 (9.1) 122 (10.1) 141 (10.1) 0.790
Metabolic Syndrome, n (%) 79 (6.0) 145 (12.0) 186 (12.9) 227 (18.9) 279 (20.0) < 0.001
Glucose (mmol/L) 4.87 (0.47) 4.95 (0.49) 5.06 (0.52) 5.15 (0.54) 5.20 (0.53) < 0.001 < 0.001
HDL Cholesterol (mmol/L) 1.58 (0.39) 1.48 (0.38) 1.44 (0.34) 1.39 (0.34) 1.36 (0.32) < 0.001 < 0.001
LDL Cholesterol (mmol/L) 2.93 (0.79) 3.05 (0.83) 3.11 (0.82) 3.21 (0.82) 3.21 (0.79) < 0.001 < 0.001
Triglycerides† (mmol/L) 0.92 1.02 1.08 1.23 1.35 < 0.001 < 0.001
Statins, n(%) 111 (8.4) 95 (7.9) 114 (7.9) 129 (10.7) 160 (11.5) 0.001
Fibrates, n(%) 9 (0.7) 13 (1.1) 12 (0.8) 20 (1.7) 12 (0.9) 0.116
Women (N = 3389) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA P for linear 
trend
GGT<8 8≤GGT<11 11≤GGT<15 15≤GGT<19 19≤GGT≤28 P Value
N = 586 670 846 620 667
Age (years) 45 (10) 46 (11) 44 (11) 45 (10) 44 (11) 0.001 0.013
Waist (cm) 81 (11) 83 (12) 82 (12) 83 (11) 82 (12) 0.037 0.697
BMI (kg/m2) 25 (5) 26 (5) 25 (5) 26 (5) 25 (5) 0.047 0.636S
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Diastolic BP (mmHg) 73 (7) 74 (8) 74 (8) 74 (8) 73 (9) 0.028 0.323
Systolic BP (mmHg) 117 (15) 118 (16) 117 (16) 117 (15) 116 (15) 0.066 0.111
Alcohol consumption (glasses/week) 0.4 (1.0) 0.4 (1.0) 0.5 (1.2) 0.5 (1.1) 0.6 (1.2) 0.098 0.058
Exercise intensity (hours/week) 1.8 (2.7) 1.9 (2.6) 1.9 (2.7) 1.8 (3.1) 1.8 (2.3) 0.869 0.802
Smoking status, n (%) 0.515
Current 107 (18.8) 137 (20.9) 165 (19.9) 106 (17.5) 113 (17.2)
Former 105 (18.5) 127 (19.3) 150 (18.1) 130 (21.5) 139 (21.1)
Hypertension, n (%) 91 (15.5) 117 (17.5) 127 (15.0) 103 (16.6) 87 (13.0) 0.216
Anti-hypertensive medications, n(%) 53 (9.0) 51 (7.6) 59 (7.0) 51 (8.2) 35 (5.2) 0.101
Metabolic Syndrome, n (%) 56 (9.6) 96 (14.3) 158 (18.7) 158 (25.5) 177 (26.5) < 0.001
Glucose (mmol/L) 4.83 (0.48) 4.96 (0.51) 5.03 (0.53) 5.15 (0.56) 5.16 (0.54) < 0.001 < 0.001
HDL Cholesterol (mmol/L) 1.63 (0.38) 1.52 (0.38) 1.46 (0.37) 1.40 (0.34) 1.40 (0.36) < 0.001 < 0.001
LDL Cholesterol (mmol/L) 2.87 (0.77) 3.03 (0.82) 3.11 (0.78) 3.20 (0.85) 3.15 (0.83) < 0.001 < 0.001
Triglycerides† (mmol/L) 0.90 0.96 1.10 1.21 1.31 < 0.001 < 0.001
Statins, n(%) 40 (6.8) 58 (8.7) 43 (5.1) 44 (7.1) 36 (5.4) 0.046
Fibrates, n(%) 4 (0.7) 6 (0.9) 2 (0.2) 1 (0.2) 4 (0.6) 0.265
* - Data are arithmetic means (S.D.) or N (%).
† - Geometric means.
List of abbreviations: GGT, gamma-glutamyl transferase; BMI, body mass index; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein.
Table 2: Patients characteristics* according to quintiles of GGT (Continued)Steinvil et al. Cardiovascular Diabetology 2010, 9:30
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performed, would barely reveal the typical changes if at
all. Therefore, quantitative analysis of liver enzymes
remains the main diagnostic tool in this situation.
The present findings are not necessarily of solely theo-
retical relevance. In fact, the elevations in the concentra-
tions of these liver enzymes might be contributory in the
etiopathogenesis of the atherothrombotic inflammatory
process. In particular, GGT might have an important role
in the extracellular catabolism of glutathione, the princi-
pal thiol antioxidant in humans [14]. In addition, this
enzyme has the ability to catalyze the oxidation of LDL-C
[38] and may also be pro-inflammatory due to the fact
that it mediates the interconversion of leukotriene C4
into D4 [39]. As mentioned, GGT may directly take part
in atherogenesis and evolve as a potential biochemical
risk indicator of cardiovascular morbidity and mortality
and thus have an application in primary and secondary
prevention of cardiovascular disease [18]. Alanine amin-
otransferase however, is considered a more liver-specific
marker than GGT. This is due to the fact that GGT is
present on the surface of most cell types and is highly
active in organs other than the liver [18]. Although both
ALT and GGT have shown predictive for diabetes in a
recent meta-analysis, GGT may be a better diabetes pre-
dictor than ALT [19]. In this regard, an increased enzyme
level in the absence of known liver disease most com-
monly reflect liver fat deposition and is representative of
the presence of visceral fat [21]. This visceral fat and obe-
sity is central to the nuclear peroxisome proliferator acti-
vated receptors (PPAR) deactivation contributing to the
development of insulin resistance, MetS and athero-
thrombosis [40,41].
The notion that persistently elevated liver enzyme con-
centrations, even within the so-called "reference" range, is
associated with cardiovascular risk factors and future dis-
ease has been previously demonstrated [42]. In fact, it has
been shown that several liver enzymes, in particular
GGT, are associated with the appearance of cardiovascu-
lar events [13]. This is also relevant to individuals with
the MetS [14]. Thus, the recognition that the prevalence
of the MetS increases even in individuals whose liver
enzymes are in the lower part of the 'normal' reference
range, might have clinical significance in terms of early
recognition of these dysmetabolic changes.
We recognize several limitations in the current analysis.
First, our conclusions are of a descriptive nature and are
based essentially only on associations between parame-
ters. Based upon its cross sectional design, the present
findings are inherently limited in the ability to eliminate
causal relationships. Second, since some of the study pop-
ulation had several risk factors, we could not fully elimi-
nate the possible effect of underlying diseases and
medications used for these diseases on the present find-
ings. Further prospective population-based studies are
needed to investigate the mechanisms in order to answer
these questions. Finally, serum GGT is a sensitive indica-
Table 3: Logistic regression analysis for the presence of MetS in relation ALT quintiles*.
Men (N = 6561) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile
ALT<16 16≤ALT<20 20≤ALT<23 23≤ALT<29 29≤ALT≤40
N 1196 1545 1121 1460 1239
Crude OR 1.0 1.5 (1.2 - 2.0) 1.7 (1.2 - 2.2) 2.7 (2.1 - 3.5) 3.6 (2.8 - 4.6)
Age adjusted OR 1.0 1.5 (1.2 - 2.0) 1.7 (1.3 - 2.3) 2.7 (2.1 - 3.5) 3.7 (2.8 - 4.8)
Multi-adjusted† OR 1.0 1.6 (1.2 - 2.1) 1.7 (1.3 - 2.3) 2.8 (2.1 - 3.6) 3.7 (2.8 - 4.8)
Multi-adjusted + waist & BMI OR 1.0 1.5 (1.2 - 2.0) 1.7 (1.2 - 2.2) 2.8 (2.2 - 3.7) 3.7 (2.8 - 4.9)
Women (N = 3389) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile
ALT<16 16≤ALT<19 19≤ALT<22 22≤ALT<27 27≤ALT≤35
N = 767 652 607 738 625
Crude OR 1.0 1.5 (1.1 - 2.0) 1.7 (1.2 - 2.3) 2.4 (1.8 - 3.2) 3.2 (2.4 - 4.2)
Age adjusted OR 1.0 1.4 (1.1 - 2.0) 1.6 (1.2 - 2.3) 2.5 (1.9 - 3.4) 3.3 (2.4 - 4.4)
Multi-adjusted† OR 1.0 1.5 (1.1 - 2.0) 1.6 (1.2 - 2.2) 2.5 (1.9 - 3.4) 3.3 (2.5 - 4.4)
Multi-adjusted + waist & BMI OR 1.0 1.4 (1.0 - 2.0) 1.7 (1.2 - 2.3) 2.6 (1.9 - 3.5) 3.3 (2.4 - 4.5)
* The lower quintile was arbitrarily defined as 1.0
† Multi-adjusted means adjustments were made for age, exercise intensity, use of aspirin and statins, smoking status and alcohol 
consumption.
List of Abbreviations: ALT, alanine aminotransferase; MetS, metabolic syndrome; OR, odds ratio.Steinvil et al. Cardiovascular Diabetology 2010, 9:30
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tor of alcohol consumption and/or liver dysfunction such
as fatty liver, and is also high in patients with liver disease:
chronic viral hepatitis, primary biliary cirrhosis, or drug-
induced liver injury. These liver diseases are present in
community-dwelling persons and are usually asymptom-
atic. Thus, these possible confounders could have
affected results.
We conclude that a relatively high prevalence of the
MetS has been noted in a cohort of apparently healthy
individuals who have within-normal-limits concentra-
tions of liver enzymes. The relatively high prevalence of
the MetS observed could explain, at least in part, the pre-
viously noted epidemiological associations between ele-
vated concentrations of GGT and ALT and future
vascular risk. Moreover, our findings suggest that even
minute changes, still within the so called "normal range"
could point towards a potential dysmetabolic state. These
observations could therefore lead to avoiding the usage of
cut-off values for normalcy for these two biomarkers. In
addition, they should encourage the use of both GGT and
ALT as continuous biomarkers that could be used for
early signaling of dysmetabolism. Finally, our results sup-
port the notion that in the era of early detection, preven-
tion and treatment of metabolic disorders, one cannot be
confident that relatively low concentrations of liver
enzymes exclude the presence of dysmetabolic changes.
A practical consequence might therefore be to follow
these enzyme concentrations as continuous biomarkers
and take into consideration the possibility that even small
changes in their concentrations might be of relevance.
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